Amphastar Pharmaceuticals
AMPH
108 hedge funds and large institutions have $365M invested in Amphastar Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 34 increasing their positions, 48 reducing their positions, and 16 closing their positions.
23% more capital invested
Capital invested by funds: $296M → $365M (+$68.9M)
0.21% more ownership
Funds ownership: 44.49% → 44.7% (+0.21%)
7% less funds holding
Funds holding: 116 → 108 (-8)
29% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 48
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $16K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$18M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.29M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.73M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$3.39M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.4M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$4.19M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.17M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.84M |
| 5 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$2.67M |
AMPH Hedge Fund Activity: Q2 2017 in Review
108 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2017, worth a combined $365M — up 23% from $296M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AMPH and 9 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 34 added.
The largest buyer was Invesco, adding an estimated $18M. The largest seller was Fidelity Investments, exiting entirely with an estimated $4.4M sold.
- 108 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2017, down from 116 in Q1 2017.
- Funds reported $365M of Amphastar Pharmaceuticals stock for Q2 2017, up 23% quarter-over-quarter.
- 9 funds opened new Amphastar Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of -7 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2017 was Invesco, an estimated $18M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2017 was Fidelity Investments, an estimated $4.4M sold.
Based on aggregated 13F filings for Q2 2017.